Europe Breast Cancer Screening Tests Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 0.83 Billion |
| Market Size (2029) | USD 1.26 Billion |
| CAGR (2024 - 2029) | 8.68 % |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Europe Breast Cancer Screening Tests Market Analysis
The Europe Breast Cancer Screening Tests Market size is estimated at USD 0.83 billion in 2024, and is expected to reach USD 1.26 billion by 2029, growing at a CAGR of 8.68% during the forecast period (2024-2029).
The studied market is anticipated to grow during the projected period owing to the growing incidence of breast cancer, government initiatives for early detection of breast cancer, and a high number of clinical trial developments and technological advancements in tests.
The high burden of breast cancer in Europe is anticipated to propel the demand for breast cancer screening tests during the forecast period. For instance, according to the European Breast Cancer Coalition 2023, breast cancer was the most commonly diagnosed cancer in Europe in 2023, with around 380,000 new cases, primarily among women. This disease represented 13.8% of all cancer diagnoses within the EU. Projections suggest that breast cancer cases will continue to rise, driven by an aging population and certain lifestyle factors. In response, the European Commission, under its Beating Cancer Plan, is intensifying screening programs. Their goal is to achieve a 90% screening rate for eligible populations by 2025, aiming to bolster early detection and treatment outcomes. Thus, the high burden of breast cancer in the European region is expected to accelerate the demand for breast cancer screening tests, thereby propelling the market growth during the forecast period.
Furthermore, the rising clinical trials for the development and evaluation of screening tests are also contributing to the market growth. For instance, as per clinicaltrials.gov, a clinical trial, sponsored by the University Medical Center in Utrecht, Netherlands, is slated for completion by April 2023. This study aims to assess the cost-effectiveness of biennial screenings using both mammography and MRI, in contrast to mammography alone, for women aged 50-75 exhibiting over 75% mammographic density. The high number of clinical trials are expected to create an opportunity for market players to develop advanced screening tests, which are further expected to boost the market growth.
Further, rising government and private organization initiatives to support breast cancer screening in Europe are expected to propel the adoption of breast cancer screening tests, boosting the market growth. For instance, European Society of Radiology (ESR) announced that the European Commission’s Joint Research Centre (JRC), in collaboration with the Directorate General for Health and Food Safety (DG SANTE), has established a new Working Group. This group is tasked with crafting guidelines for breast cancer screening and diagnosis. The initiative seeks to set forth detailed requirements for breast cancer services, covering the entire care pathway. Such guidelines will fuel the adoption of breast cancer diagnostics and is likely to contribute the segment growth over the projected period.
Therefore, owing to the aforementioned factors, such as the high burden of breast cancer, rising clinical trial developments, and government initiatives, the studied market is anticipated to grow over the projected period. However, the high cost of breast cancer screening tests, side effects of radiation during screening tests, and errors in screening are likely to impede the market growth.
Europe Breast Cancer Screening Tests Market Trends
Mammograms Expected to Hold a Major Share in the Europe Breast Cancer Screening Test Market Over The Forecast Period
Mammograms are the most commonly utilized tests for detecting breast cancer. Mammography, recognized as the gold standard technique, plays a crucial role in early breast cancer detection and significantly improves treatment outcomes.
In Europe, governments and healthcare organizations are actively ensuring that women aged 50 to 75 have access to mammography screenings. This push is driving up the demand for mammography services. Concurrently, laboratory blood tests and various imaging tests are also witnessing a surge in popularity. For instance, in January 2023, according to the Department of Health and Social Care, NHS England, the government allocated GBP 10 million (USD 12.2 million) to deliver 29 new breast cancer screening units to speed up breast cancer diagnosis and treatment. Thus, such government initiatives are likely to increase mammogram adoption, driving the segment growth.
The increase in strategic initiatives such as agreements and partnerships to provide mammograms in the European region is expected to propel the segment growth over the forecast period. For instance, in March 2024, Lunit signed a supply contract with TeleDiag in France and the Portuguese League Against Cancer (Liga Portuguesa Contra o Cancro; LPCC). These contracts provide AI-driven radiology solutions: chest X-ray detection in collaboration with TeleDiag and breast cancer detection with LPCC. Additionally, Lunit has entered into another agreement with the central region branch of LPCC, supplying its FDA-cleared and CE-marked AI solution for mammography analysis, known as Lunit INSIGHT MMG. Such an agreement will increase the supply of mammograms in the market owing to increasing demand, likely to contribute to the segment growth.
Furthermore, market players' new product introductions are poised to boost the segment's growth. For instance, in February 2024, Fujifilm unveiled its cutting edge mammography technology, Amulet Sophinity, at the European Congress of Radiology (ECR) annual meeting in Vienna, Austria, from February 28 to March 3, 2024. As highlighted in a press release, this groundbreaking technology aimed to boost the accuracy and convenience of breast cancer diagnoses, all while prioritizing patient comfort and upholding superior image quality. Such technological strides in mammograms are poised to spur demand and propel segment growth throughout the forecast period.
Consequently, due to these factors including heightened government initiatives promoting breast screening and a surge in clinical trials for advanced mammograms, the segment is poised for substantial growth in the coming years.
Germany is Expected to Hold a Significant Share in the Europe Breast Cancer Screening Tests Market Over the Forecast Period
Germany is poised to command a substantial share of the market owing to factors such as the high burden of breast cancer and rising awareness initiatives, increasing development and product launches for breast cancer screening.
The awareness campaigns in the country are anticipated to accelerate market growth over the projected period. For instance, In a bid to bolster awareness for breast cancer prevention, Munich's Königsplatz was illuminated in pink from October 11 to 13, 2023, as part of Estée Lauder Companies' Breast Cancer Campaign 2023. Such awareness initiatives are expected to increase the utility of breast cancer screening in the country, thereby augmenting the market growth during the projected period.
Several initiatives taken to increase access to mammography in Germany for women are likely to contribute to market growth. For instance, in Germany, women aged 50 to 75 are entitled to a complimentary mammogram biennially, which ceases on their 76th birthday. The primary goal of the screening is to identify breast cancer at its earliest stage, thereby enhancing treatment efficacy and boosting recovery odds. Thus, such initiatives will support the adoption of mammography for breast cancer diagnosis is anticipated to propel the market growth over the projected period.
Further, increasing funding for the development of breast cancer is expected to propel the market growth over the forecast period. For instance, in November 2024, Vara, a Berlin-based enterprise utilizing AI to enhance breast cancer screenings, announced it has secured GBP 8.2 million (USD 8.8 million) to support its expansion across Europe. The company's AI-powered software aims to improve the accuracy and efficiency of breast cancer detection. Such funding initiatives that provide access to these breast cancer screening tests are likely to boost its demand, contributing to the market growth.
Therefore, owing to factors such as the rising launches of screening tests by market players and increasing awareness initiatives in the country, the country is expected to witness growth during the forecast period.
Europe Breast Cancer Screening Tests Industry Overview
The Europe breast cancer screening test market is semi-consildated and consists of several major players. In terms of market share, a few of the major players currently dominate the market. With the increasing awareness among the population and rising advances in screening test, a few other smaller players are expected to enter the market and may come to hold a substantial share. Some of the major players in the market are Allengers, Myriad Genetics, Hologic Inc., and Siemens Healthineers, among others.
Europe Breast Cancer Screening Tests Market Leaders
-
Allengers
-
Myriad Genetics, Inc.
-
Siemens Healthineers
-
Hologic Inc.
-
GE Healthcare
*Disclaimer: Major Players sorted in no particular order
Europe Breast Cancer Screening Tests Market News
- August 2024: Izotropic Corporation has revealed its intent to adopt a regulatory strategy in both the United States and European Union. The goal is to introduce IzoView as a diagnostic tool, specifically targeting patients with dense breast tissue. This condition, a typical variation, is linked to a heightened risk of developing breast cancers.
- May 2024: Hologic, Inc. has introduced the 7-gauge needle for its Brevera Breast Biopsy System in Europe. This expansion of the Brevera Disposable Biopsy Needles lineup offers radiologists enhanced choices for their biopsy procedures.
Europe Breast Cancer Screening Tests Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Incidence of Breast Cancer and Government Initiatives for Early Detection of Breast Cancer
4.2.2 Increasing Clinical Trial Developments and Technological Advancements in Tests
4.3 Market Restraints
4.3.1 High Cost of Breast Cancer Screening Tests
4.3.2 Side Effects of Radiation during Screening Tests and Errors in Screening
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Test Type
5.1.1 Genomic Tests
5.1.2 Imaging Test
5.1.2.1 Mammograms
5.1.2.2 Ultrasound
5.1.2.3 MRI
5.1.2.4 Tomography
5.1.2.5 Other Imaging Tests
5.2 Geography
5.2.1 Germany
5.2.2 France
5.2.3 United Kingdom
5.2.4 Italy
5.2.5 Spain
5.2.6 Rest of Europe
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allengers
6.1.2 Agendia Inc.
6.1.3 Myriad Genetics, Inc.
6.1.4 Koninklijke Philips N.V.
6.1.5 GE Healthcare
6.1.6 Fujifilm Holdings Corporation
6.1.7 NanoString Technologies, Inc.
6.1.8 Siemens Healthineers
6.1.9 Hologic Inc.
6.1.10 Quest Diagnostics Incorporated
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Europe Breast Cancer Screening Tests Industry Segmentation
As per the scope of the report, breast cancer screening is carried out to detect cancer in its early stages and ensure timely treatment for the patients. Breast cancer can affect different parts of the breast, such as the ducts and the lobes.
The Europe breast cancer screening tests market is segmented by test type and geography. Based on test type the market is segmented as genomic tests and imaging tests. Based on geography the market is segmented as Germany, France, the United Kingdom, Italy, Spain, and the Rest of Europe. The report offers the market size in value terms in USD for all the abovementioned segments.
| By Test Type | |||||||
| Genomic Tests | |||||||
|
| Geography | |
| Germany | |
| France | |
| United Kingdom | |
| Italy | |
| Spain | |
| Rest of Europe |
Europe Breast Cancer Screening Tests Market Research FAQs
How big is the Europe Breast Cancer Screening Tests Market?
The Europe Breast Cancer Screening Tests Market size is expected to reach USD 0.83 billion in 2024 and grow at a CAGR of 8.68% to reach USD 1.26 billion by 2029.
What is the current Europe Breast Cancer Screening Tests Market size?
In 2024, the Europe Breast Cancer Screening Tests Market size is expected to reach USD 0.83 billion.
Who are the key players in Europe Breast Cancer Screening Tests Market?
Allengers, Myriad Genetics, Inc., Siemens Healthineers, Hologic Inc. and GE Healthcare are the major companies operating in the Europe Breast Cancer Screening Tests Market.
What years does this Europe Breast Cancer Screening Tests Market cover, and what was the market size in 2023?
In 2023, the Europe Breast Cancer Screening Tests Market size was estimated at USD 0.76 billion. The report covers the Europe Breast Cancer Screening Tests Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Breast Cancer Screening Tests Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Europe Breast Cancer Screening Tests Industry Report
Statistics for the 2024 Europe Breast Cancer Screening Tests market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Breast Cancer Screening Tests analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Europe Breast Cancer Screening Tests Market Report Snapshots
